Email Updates

You are here

HVTN 106

Status
Ongoing
Phase
I
Principal Investigator(s)
Lindsey Baden, Brigham and Women's Hospital
Objective

The purpose of this study is to evaluate the safety and immune response to three DNA vaccines and a MVA-CMDR vaccine that may boost the immune response to the DNA vaccines in healthy, HIV-uninfected adults.

 

*Trial is in follow-up*

Prevention Option(s)
HIV Vaccine
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Description
Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
Mode of Delivery
Intramuscular
Products
DNA
MVA
ARMs
Experimental
Description
Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
Mode of Delivery
Intramuscular
ARMs
Placebo Comparator
Description
Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
Mode of Delivery
Intramuscular
Products
DNA
MVA
ARMs
Experimental
Description
Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
Mode of Delivery
Intramuscular
ARMs
Placebo Comparator
Description
Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
Mode of Delivery
Intramuscular
Products
DNA
MVA
ARMs
Experimental
Description
Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
Mode of Delivery
Intramuscular
Products
DNA
MVA
ARMs
Placebo Comparator
Trial Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), CHAVI, IPPOX, MHRP, HIV Vaccine Trials Network
January 2015
September 2020
Enrollment
105
18
Years
50
Years
Population
Women
Men
Sites

Alabama Vaccine CRS

Birmingham, Alabama
United States of America

Bridge HIV CRS

San Francisco, California
United States of America

Hope Clinic of the Emory Vaccine Center CRS

Decatur, Georgia
United States of America

Brigham and Women's Hospital CRS

Boston, Massachusetts
United States of America

Fenway Health (FH) CRS

Boston, Massachusetts
United States of America

Seattle Vaccine Prevention CRS

Seattle, Washington
United States of America

Lausanne Vaccine and Immunotherapy Center CRS

Lausanne
Switzerland